Why the study?
Atherogenic dyslipidemia and NAFLD share a bi-directional relationship and drive ASCVD, warranting early detection and treatment; thus, integrative screening and management programs are urgently needed.
Early detection and a stepwise management approach for dyslipidemia in NAFLD patients are crucial for mitigating atherosclerotic cardiovascular disease risk.
Answers are grounded in this paper and cite their sources.
May support stepwise dyslipidemia management in NAFLD to mitigate ASCVD; leaves open prospective trials for validation.
Atherogenic dyslipidemia in patients with NAFLD results from hepatic and peripheral insulin resistance along with associated alterations of hepatic glucose and lipoprotein metabolism, gut dysbiosis, and genetic factors. Since atherogenic dyslipidemia and NAFLD share a bi-directional relationship and are both major driving forces of atherosclerotic cardiovascular disease (ASCVD) development, early detection and adequate treatment are warranted. Thus, integrative screening and management programs are urgently needed. A stepwise approach for dyslipidemic patients with NAFLD includes (i) characterization of dyslipidemia phenotype, (ii) individual risk stratification, (iii) definition of treatment targets, (iv) lifestyle modification, and (v) pharmacotherapy if indicated.
No takes yet. Share an insight, caveat, or question.
Martin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: